---
title: "Trastuzumab Rezetecan in HER2-Expressing Advanced Gastric Cancer and Related Cancers: A Multicen"
id: "journal-of-clinical-oncology-34-trastuzumab-rezetecan-in-human-epidermal-growth-factor-receptor-2-expressing-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma-and-colorectal-cancer-a-multicenter-open-label-phase-i-trial"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-34-trastuzumab-rezetecan-in-human-epidermal-growth-factor-receptor-2-expressing-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma-and-colorectal-cancer-a-multicenter-open-label-phase-i-trial"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Journal of Clinical Oncology (JCO)"
source_url: "https://ascopubs.org/doi/abs/10.1200/JCO-25-00716?af=R"
published_at: "2026-03-04T08:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trastuzumab Rezetecan in HER2-Expressing Advanced Gastric Cancer and Related Cancers: A Multicen
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-34-trastuzumab-rezetecan-in-human-epidermal-growth-factor-receptor-2-expressing-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma-and-colorectal-cancer-a-multicenter-open-label-phase-i-trial
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Journal of Clinical Oncology (JCO)
- **Source URL:** [Original Journal Publication](https://ascopubs.org/doi/abs/10.1200/JCO-25-00716?af=R)
- **Published At:** 2026-03-04T08:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 04 Mar 2026. The item focuses on Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 04 Mar 2026. The item focuses on Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. Review the original article for the full source wording and details.
## Related Clinical Research

- [HER2-Targeted Therapy in Metastatic Colorectal Cancer: Evidence, Testing, and Sequencing](https://medichelpline.com/clinical-feed/pubmed-42663748.md) (DOI: 10.1007/s12029-026-01564-1)
- [Antibody-Drug Conjugates for Advanced Esophageal Cancer: Targets, Evidence, and Clinical Integrati](https://medichelpline.com/clinical-feed/pubmed-42700288.md) (DOI: 10.1007/s11864-026-01411-2)
- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [CDCTNet: Transformer–CNN hybrid for colorectal lesion diagnosis](https://medichelpline.com/clinical-feed/plos-one-7-colorectal-lesion-diagnosis-using-transformer-and-deep-learning-with-multiscale.md)
- [Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development](https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.